Guest Editor(s)
Assist. Prof. Daniela Gabbia
Email: daniela.gabbia@unipd.it
Affiliation: Department of Pharmaceutical and Pharmacological Sciences, University of Padova
Address Largo Meneghetti, 2 - 35131 Padova, Italy
Homepage:
Research Interests: hepatocellular carcinoma, chronic liver disease, pharmacology, preclinical studies
Summary
Liver cancer, primarily hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), represents a significant global health problem due to its rising risk for mortality, late diagnosis, poor prognosis, and limited effective treatment options. HCC accounts for the majority of liver cancer cases and is frequently linked to chronic liver diseases, such as hepatitis C infections, alcohol- and metabolic-related steatotic disease, e.g., ALD, MASLD, and MASH. Despite advances in systemic therapies, e.g., combined immunotherapies, survival outcomes remain unsatisfactory, due to the complex molecular heterogeneity of liver cancers and pathogenetic mechanisms. Cholangiocarcinoma, a malignancy arising from the bile ducts is less common than HCC, has been increasing in incidence worldwide, and poses unique diagnostic and therapeutic challenges that warrant focused investigation. Integrating novel biomarkers for early diagnosis, prognosis, and treatment response assessment is urgently needed to improve clinical management and personalization of the therapy to achieve an improvement in the poor overall survival.
Aim and Scope:
This Special Issue focuses on the latest research regarding novel therapeutic strategies and biomarkers for hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), covering studies from preclinical models to clinical applications. It welcomes original research, comprehensive reviews, and translational studies investigating innovative molecular targets, combination therapies, and emerging technologies like single-cell sequencing, advanced imaging, and artificial intelligence applications in liver cancer research and treatment. The issue aims to promote multidisciplinary collaboration and accelerate translational research for improved liver cancer management.
Topics of interest:
· Novel biomarker discovery and validation for liver cancer early detection and prognosis
· Innovative treatment modalities, including but not limited to kinase inhibitors, immunotherapies, and combination regimens
· Molecular and cellular targets for therapeutic intervention in HCC and CCA
· Preclinical models and their utility in evaluating novel therapeutics
· Immunotherapy approaches and tumor microenvironment modulation
· Combination therapies and overcoming drug resistance in liver cancers
· Applications of artificial intelligence and multi-omics technologies in liver cancer research
Keywords
liver cancer, HCC, CCA, hepatology, drug discovery, biomarkers
Published Papers
Login
Register
Submit a Paper
Propose a Special lssue